Poland· PL-100509279
Edurant
A rilpivirine product containing rilpivirini hydrochloridum, registered in Poland by Janssen-Cilag International N.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Rilpivirine is registered in 14 of 19 countries.
Countries holding a registration under ATC J05AG05 (rilpivirine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Rilpivirine · ATC J05AG05
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rilpivirine costs, country by country.
Normalised to the WHO defined daily dose (25 mg), the median price runs from $6.77 in France to $13.46 in Switzerland — a ×2.0 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Rilpivirine · price per daily dose (25 mg)
USD · FX 28 Sept 2026
- CH Switzerland$13.46
- FR France$6.77
The record
At a glance
URPL (Poland)- Active substance
- Rilpivirini hydrochloridum
- Manufacturer
- Janssen-Cilag International N.V.
- Country
- Poland (PL)
- ATC code
- J05AG05
- ATC class
- Rilpivirine
- Defined daily dose
- 25 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05413868126822
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
239 interactions on record for rilpivirine.
Graded by severity as the source publishes them — 58 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rilpivirine · interactions on record
239 records
- 58 severe
- 179 moderate
- 2 minor
Most severe, free to view
- CimetidineA02BA01severe
- RanitidineA02BA02severe
- FamotidineA02BA03severe
- NizatidineA02BA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rilpivirine in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumEdurant 2.5 mgJanssen-Cilag International
- SwitzerlandEdurant 2.5 mg, Tabletten zur Herstellung einer Suspension zum EinnehmenJanssen-Cilag AG
- FinlandEdurantJanssen-Cilag International NV
- IrelandEDURANT 2.5 mg film-coated tabletsJanssen-Cilag International NV
- NetherlandsEDURANT 2,5 mg dispergeerbare tablettenJanssen-Cilag International NV
- SwedenEDURANT 2,5 mg Dispergerbar tablettJanssen-Cilag International NV
- United StatesEDURANT PEDJanssen Products, LP
- CzechiaEDURANTJanssen-Cilag International N.V., Beerse
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Edurant, Rekambys
- Liechtenstein · Edurant, Rekambys
- Norway · Edurant, Rekambys
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d5055179-0cc9-4938-b255-5d6e2aac1fc4 GET /v1/drugs/d5055179-0cc9-4938-b255-5d6e2aac1fc4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki do sporządzania zawiesiny doustnej",
"source": "urpl",
"strength": "2,5 mg",
"packaging": "05413868126822 ¦ Rpz ¦ EU/1/11/736/002 ¦ 159315\n90 tabl. w blistrze perforowanym",
"substance": "Rilpivirini hydrochloridum 2.5 mg",
"common_name": "Rilpivirini hydrochloridum",
"pl_product_id": "100509279",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about rilpivirine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.